Abstract
Research question
What is the real-world effectiveness of Fertistartkit® in women undergoing assisted
reproductive technology (ART)?
Design
Retrospective cohort study including anonymized data of women undergoing ovarian stimulation
for ART with Fertistartkit between April 2016 and November 2017 and follow-up of clinical
outcomes up to February 2018. Data were collected from the electronic patient databases
of 12 French ART centres. The main outcome was number of oocytes retrieved. All data
were categorized according to female age (<25, 25–29, 30–34, 35–37, 38–39 and >39
years).
Results
A total of 1006 cycles from 914 women treated with Fertistartkit were included. At
the time of first ovarian stimulation in the study, women were 34.9 ± 5.0 years old,
with a median body mass index of 22.7 kg/m². Couples had been infertile for more than
4 years, with all patterns of causes of infertility. Ovarian stimulation was started
with a median dose of 300 IU (interquartile range [IQR]: 150–300 IU) of Fertistartkit
for 10 days (IQR: 9–11 days), so a median total dose of 2700 IU (IQR: 1800–3300 IU).
The mean number of oocytes retrieved per cycle was 9.5 ± 6.8, and the mean number
of mature oocytes per cycle was 7.4 ± 5.5. The obtained ongoing pregnancy per started
cycle was 26.0% (95% confidence interval [CI]: 24.1–27.9) and the obtained ongoing
pregnancy per puncture was 27.0% (95% CI: 25.0–29.0).
Conclusions
This is the first cohort to describe Fertistartkit treatment management in real-life
conditions. The real-world data show that Fertistartkit is an effective option for
ovarian stimulation.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Reproductive BioMedicine OnlineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF.Gynecol. Endocrinol. 2013; 29: 695-699
- A systematic review of tests predicting ovarian reserve and IVF outcome.Hum. Reprod. Update. 2006; 12: 685-718
- Le rapport médical et scientifique de l'assistance médicale à la procréation et de la génétique humaines en France.Activité d'Assistance Médicale à la Procréation. 2016; (2016)
- ‘Model’ versus ‘everyday’ patients: can randomized controlled trial data really be applied to the clinic?.Reprod. Biomed. 2017; 34 (Online): 274-279
- Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.Clinics (Sao Paulo). 2014; 69: 279-293
- A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources.Reprod. Biomed. Online. 2017; 35: 17-27
- Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.Fertil. Steril. 2018; 109: 968-979
- The role of LH in ovarian stimulation.Curr Pharm Biotechnol. 2012; 13: 409-416
- Forty years of IVF.Fertil. Steril. 2018; 110 (.e5): 185-324
- Management Strategies for POSEIDON's Group 1.Front Endocrinol (Lausanne). 2019; 10: 679
- Real-World Evidence of Treatment Effects: The Useful and the Misleading.Clin. Pharmacol. Ther. 2019; 106: 43-44
Biography
Paul Barrière, MD, PhD, graduated from Nantes University and founded the ART Center in CHU Nantes, one of the largest public centres and one of five PGD programmes in France. He has had a longstanding interest in ovarian stimulation since the late 1980s, since his work on agonist protocols.
Key Message
In a real-world setting, Fertistartkit® is an efficient and safe option for controlled ovarian stimulation in assisted reproductive technology. It appreciates and completes the knowledge gained from previous randomised clinical trials, as it concerns larger, non-selected and more inclusive populations of patients and practitioners that better reflect actual practices.
Article info
Publication history
Published online: January 09, 2020
Accepted:
January 2,
2020
Received in revised form:
December 10,
2019
Received:
October 16,
2019
Declaration: PB has served on a scientific advisory board for Laboratoires Genevrier. All other authors report no financial or commercial conflicts of interest.Identification
Copyright
© 2020 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
